This inventor holds 1 USPTO granted patent. Top assignee: American Cyanamid Company. Active years: 1998.
Company Filing History:
Years Active: 1998
Title: Innovations of James P. LaRocque
Introduction
James P. LaRocque is an accomplished inventor based in Highland Mills, NY (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of antiviral agents. His innovative work has led to the creation of a patent that addresses viral infections, showcasing his expertise and dedication to improving public health.
Latest Patents
James P. LaRocque holds a patent for "Triazine containing anionic compounds useful as antiviral agents." This invention provides triazine ring containing anionic compounds, pharmaceutical compositions containing these compounds, and methods utilizing these compounds for treating viral infections, particularly infections by respiratory syncytial virus. The compounds have the general structure: ##STR1## and the pharmaceutically acceptable salt thereof. This patent highlights his commitment to advancing medical science and finding effective treatments for viral diseases.
Career Highlights
Throughout his career, LaRocque has been associated with the American Cyanamid Company, where he has contributed to various research and development projects. His work has not only led to innovative solutions but has also positioned him as a key figure in the pharmaceutical industry. His dedication to research and development has resulted in impactful advancements in antiviral therapies.
Collaborations
James P. LaRocque has collaborated with notable colleagues, including Yakov Gluzman, who is deceased, and Bryan M. O'Hara. These collaborations have fostered a productive environment for innovation and have contributed to the success of their projects.
Conclusion
James P. LaRocque's contributions to the field of pharmaceuticals through his innovative patent demonstrate his commitment to addressing critical health challenges. His work continues to inspire future advancements in antiviral treatments.